Related Experiment Video
Updated: Jun 24, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Safety of an IV formulation of carbamazepine
Jeannine M Conway1, James R White, Angela K Birnbaum
1Experimental and Clinical Pharmacology, University of Minnesota, 5-130 WDH, 308 Harvard St. S.E., Minneapolis, MN 55455, United States. pluha003@umn.edu
Abstract:
An intravenous formulation of carbamazepine (CBZ) was administered to 113 (60 male; 53 female) persons with epilepsy aged 19-87 years. Subjects received 100mg of study drug as replacement for 100mg of their usual morning dose of CBZ. There were no significant changes in blood pressure or heart rate suggesting that this formulation can be developed as replacement therapy for persons unable to take oral CBZ.
Related Concept Videos
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
One-Compartment Open Model for IV Bolus Administration: General Considerations
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant, half-life,...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Drug Dosing: Infants and Children
IV Infusion to Oral Dosing: Conversion Methods
